Juvmo, the brand name for tavapadon, became the 43rd entry on the FDA’s 2026 novel drug approvals list on September 25, 2026. AbbVie’s once-daily tablet is cleared for adults with Parkinson’s disease, a condition that affects roughly a million Americans. It is the first drug in its class to reach Parkinson’s patients, and it works on dopamine signaling in a way older medicines do not.
The approval is one of 46 on the FDA’s novel drug approvals table for 2026, which was read on October 12, 2026. That figure is a running tally of new molecular entities approved by the agency’s drug center during the calendar year, not a final total. It leaves out biologics licensed by the separate biologics center and it does not count new uses for drugs already on the market, so three more entries have been added since Juvmo.
A selective dopamine agonist that skips most of the receptor family
Tavapadon is a selective agonist of the D1 and D5 dopamine receptors, according to a Practical Neurology summary of AbbVie’s announcement. Existing dopamine agonists such as pramipexole and ropinirole mostly act on the D2 and D3 receptors, which are linked to some of the better-known side effects of that drug group. By targeting a different receptor subset, tavapadon aims to restore movement control through another door. Whether that selectivity translates into fewer problems in everyday use is a question the approval trials could not settle by themselves, and it will be answered by prescribing experience over the coming years.
AbbVie framed the approval as a milestone for the field. Roopal Thakkar, the company’s executive vice president for research and development and chief scientific officer, said that “the approval of Juvmo marks the first dopaminergic breakthrough for Parkinson’s disease in decades,” as Contract Pharma reported. He added that clinicians now have a new option that targets dopamine pathways differently.
TEMPO phase 3 endpoints and results
The approval rests on a phase 3 program called TEMPO. The first two studies, TEMPO-1 and TEMPO-2, enrolled people with early Parkinson’s disease who were not yet taking levodopa and compared tavapadon with placebo. The third, TEMPO-3, tested tavapadon added to levodopa in people whose symptoms fluctuated through the day. Results for TEMPO-2 were not included in the summary reviewed for this article.
In TEMPO-1, patients on 5 mg and 15 mg doses improved on the MDS-UPDRS Part II scale of daily activities at week 26, by 1.6 and 1.7 points, while the placebo group worsened by 0.9 points. Combined scores for daily activities and motor examination fell by 9.7 and 10.2 points on the two doses against a 1.8-point rise on placebo. Both differences carried a P value below .0001. Lower scores mean milder symptoms.
TEMPO-3 looked at the hours that matter most to patients already on levodopa. Adding tavapadon increased good “on” time without troublesome dyskinesia by 1.7 hours a day, compared with 0.6 hours on placebo plus levodopa, and cut “off” time by 1.9 hours against 0.9 hours. Both results carried P values below .001. For a patient, “off” hours are the stretches when levodopa has faded and stiffness, slowness or tremor return, so a gain of one extra hour over placebo is a practical difference rather than a point on a rating scale. The summary reviewed here did not give trial sizes or durations, which matters when weighing how far the numbers generalize.
Indication, side effects and the limits of the claim
The approval is one of 46 on the FDA’s novel drug approvals table for 2026, which was read on October 12, 2026. The FDA’s table lists the approved use as treating Parkinson’s disease in adults, and the trade reporting says Juvmo can be used with or without levodopa. It is a symptomatic therapy. The trials measured how well patients moved and functioned, not whether the underlying loss of dopamine-producing neurons slowed, so nothing in the approval supports calling it disease-modifying.
The most common adverse events were nausea, headache, dizziness, fatigue, altered taste, dyskinesia, hallucinations and low blood pressure on standing, with the pattern differing depending on whether patients took levodopa. AbbVie said most events were nonserious and mild or moderate. Dyskinesia, hallucinations and orthostatic hypotension are the effects clinicians watch most closely in this drug class.
Where a once-daily tablet fits among Parkinson’s options
Levodopa remains the strongest symptom treatment, and its benefits often wane as the disease advances. Doctors commonly delay it in younger patients because of the motor complications that build up over years. Tavapadon is positioned to occupy that early window as a stand-alone treatment, and later as an add-on when levodopa begins to wear off between doses.
AbbVie also reported longer-term data showing that after 85 weeks, 93 percent of participants had not needed a higher oral levodopa dose, and 94 percent of those with early disease had not started oral levodopa. Those figures describe a company-reported follow-up, not a head-to-head comparison against other agonists, and they say nothing about how patients on older drugs would have fared over the same period. Prescribers will also want real-world experience with the hallucination and blood-pressure effects once the tablet reaches a broader and older population than a trial enrolls. AbbVie expects Juvmo to be available in the United States in October 2026.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Long use of a common prostate pill is tied to a higher chance of glaucoma
- Ford is recalling 223,472 F-150 pickups because the fuel tank can leak or detach
- Hybrids have 15% fewer problems than gas cars, while EVs and plug-in hybrids have about 80% more, Consumer Reports finds
- Regulators cleared the first U.S. small modular reactor, 4 months early
